Glow Blend (Mini), product photo
Healing

Glow Blend (Mini)

Glow Blend Mini - compact healing and aging stack. Multi-peptide formulation for skin research.

  • Ships from Germany

Order

Unit price -
  • DHL with tracking
  • Discreet packaging
At a glance

Glow Blend (Mini) by the numbers

The key figures from our lexicon.

Full lexicon entry
Class
Healing/beauty blend
Use
Subcutaneous

in mg

Sizes
50 mg

1 size in the shop

For research and educational purposes only. Values from the TPD lexicon, sources linked there.

There is no lab analysis for Glow Blend (Mini) yet. Vote for itAll lab analyses

Knowledge

Everything about Glow Blend (Mini)

Description

Glow Blend Mini is a compact multi-peptide research formulation with focus on skin and anti-aging effects. Typical composition includes GHK-Cu, BPC-157 and smaller amounts of further healing or aging peptides in one injection.

Per study reports the formulation combines mechanisms relevant in skin research: GHK-Cu for collagen synthesis and gene expression regulation, BPC-157 for connective tissue repair, plus possible additional active ingredients like TB-500 for actin mobilization.

The “Mini” designation indicates a more compact compound amount per vial vs full Glow Blend formulations - typical for shorter research protocols or for users preferring lower total compound amounts.

Typical application is subcutaneous once daily in 6-10 week courses.

You can order Glow Blend Mini as lyophilized peptide in 10-pack.

This information is for research and educational purposes only. No medical recommendations.

Risks & Safety

Glow Blend Mini is considered well tolerated per study reports. The included compounds - GHK-Cu, BPC-157 and further healing peptides - each have a mild profile in the preclinical literature.

Observed in research and user reports:

  • Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
  • Copper component: as a copper-containing formulation, the GHK-Cu component can cause somewhat more pronounced local irritation at the injection site than pure peptide solutions.
  • Circulation: isolated reports of brief fatigue or a feeling of warmth shortly after application.
  • No long-term data: robust long-term human studies do not exist for the individual compounds. The exact blend composition is less well characterized than the separate peptides.

This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

Good to have

What you need with it

Bacteriostatic water is added to your cart automatically. Syringes and swabs with one click.

automatic

Bacteriostatic water

Matched to your amount, price in the cart.

Insulin Syringes

10 pcs · 5.50 €

Alcohol Swabs

50 pcs · 10 €

How much water?

Units on the syringe for your vial size.

Open calculator →

FAQ

Frequently asked

Sources for every answer: lexicon entry

Still have a question?

Write to us, our team will help you.

Are there studies on the Glow Blend?

No. As of 26 October 2026 there is no study on the ready-made blend, neither on ClinicalTrials.gov nor in PubMed. All three compounds together only appear in reviews. The components have been studied, almost always each on its own.

What is the difference from the large Glow Blend?

It is the same mix of BPC-157, TB-500 and GHK-Cu, just in a smaller vial. The evidence is identical for both, since only the single components have been studied.

Is the combination stronger than the single compounds?

That has not been studied. In the only study with two of the three components (tendon healing in rats), BPC-157 plus TB-500 gave no advantage over either compound alone. The authors suspect that both act on shared pathways. There are no data on GHK-Cu in combination.

How well has BPC-157 been studied in humans?

Barely. A systematic review found 36 studies: 35 in animals or cells and one retrospective analysis of 12 people with knee pain. A second review from 2026 counted three small human studies with 30 people in total and rated the evidence as very low.

Is TB-500 the same as thymosin beta-4?

Not quite. TB-500 is described as a fragment of thymosin beta-4. The studies, including the wound healing in rats and the phase 1 trial into a vein, used full thymosin beta-4. We found no study with TB-500 itself.

Which side effects are known?

There are no data for the blend. The three small BPC-157 human studies reported no treatment-related side effects. Thymosin beta-4 was well tolerated in a phase 1 trial into a vein. Solid long-term data are missing for all three. Reviews also warn about contamination from unregulated manufacturing.

Is the Glow Blend approved?

No. Neither the blend nor any of the three components is approved as a medicine (as of October 2026). The least studied are BPC-157 (phase 1 as the highest phase in ChEMBL) and GHK-Cu (only an early phase 1 trial in the registry), which is why phase 1 is shown as the stage here.

Related

Related products